Physician profile
Garrett Rowe
NPI 1790212520
$10,179.50
in general payments reported to CMS, 2019-2025
42 companies · $1,547 in 2025
The $1,547 reported for 2025 was more than what 92% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14.69 · 2020: $518 · 2021: $2,143 · 2022: $2,099 · 2023: $2,079 · 2024: $1,778 · 2025: $1,547.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,345 · Education: $60.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,344.78 |
| Education | $60.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,554.40 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $820.09 | 2020-2025 | Jardiance, Mounjaro, Zepbound |
| Abbvie INC. | $805.62 | 2021-2024 | Vraylar, Qulipta, Ubrelvy |
| Glaxosmithkline, LLC. | $732.27 | 2020-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| E.R. Squibb & Sons, L.L.C. | $640.22 | 2021-2025 | Eliquis, Camzyos |
| Pfizer INC. | $581.69 | 2020-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $456.57 | 2020-2025 | Jardiance, Spiriva Respimat, Stiolto Respimat |
| Novartis Pharmaceuticals Corporation | $449.01 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $424.82 | 2022-2025 | |
| Amgen INC. | $375.12 | 2020-2023 | Otezla, Repatha |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $335.14 | 2020-2025 | Xifaxan |
| Astrazeneca Pharmaceuticals LP | $325.78 | 2020-2025 | Airsupra, Farxiga, Breztri |
| Amarin Pharma, INC. | $247.58 | 2020-2022 | |
| Xeris Pharmaceuticals, INC. | $247.22 | 2021-2025 | Gvoke Hypopen |
| Esperion Therapeutics, INC. | $219.12 | 2021-2025 | Nexletol |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Garrett Rowe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.